Adding baricitinib to standard treatment for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether adding a drug called baricitinib to your usual TPO-RA treatment works better than TPO-RA alone for people with ITP who haven't responded enough to TPO-RA. It aims to see if the combination helps raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- You have been diagnosed with immune thrombocytopenia (ITP).
- You have tried a full dose of a TPO-RA medicine (like eltrombopag or romiplostim) for at least 14 days and it did not bring your platelets to a safe level.
- Your platelet count is below 30, or between 30 and 50 with bleeding symptoms.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You do not have active infections, cancer, or serious heart or blood vessel conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This study compares two treatments for people with ITP (low platelets) whose condition didn't improve after steroids. One group gets only eltrombopag (a platelet booster pill) and the other gets eltrombopag plus ripertamab (an experimental antibody). The goal is to see if the combination works better at raising platelet levels.
This study tests a new combination of two medicines to help raise platelet counts in people with persistent or chronic immune thrombocytopenia (ITP) whose platelets are still low after standard treatments. The goal is to see if this combination works better and is safe.
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.